Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$58.04

 0.48 (0.82%)

High$59.08
Low$57.30
Volume408,979
Market Cap$8,283,660,844

01/24/17  3:53 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2016 Financial Results on February 9, 2017 01/19/17

Read more

Seattle Genetics Initiates Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma 01/05/17

Read more

Events

4th Quarter & Year 2016 Financial Results Conference Call02/09/17 1:30 p.m. PTView event35th Annual J.P. Morgan Healthcare Conference01/09/17 2:30 p.m. PTView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources